Company commercializes technology from Cincinnati Children's and Mayo
Clinic to help doctors select right drug at right dose for patients
CINCINNATI, March 5 /PRNewswire/ -- AssureRx, a personalized medicine
company, today announced that it has closed a round of funding.
The company was founded in 2006 to license and commercialize
pharmacogenetic technology from Cincinnati Children's Hospital Medical
Center and Mayo Clinic. The technology utilized in the AssureRx
non-invasive, pharmacogenetic test measures, analyzes and interprets the
genes of patients with common neuro-psychiatric disorders to predict which
drugs are best choices for each specific patient. The test helps to take
much of the guesswork out of prescribing medications.
"Personalized medicine is the future of health care," said Mark Byrne,
chief executive officer of AssureRx. "Our test uses cutting-edge technology
to measure, analyze and inform, helping doctors provide customized care
based on science. Our comprehensive genetic test, sophisticated
interpretive algorithms, quick turnaround and physician-friendly reports
provide physicians a unique guide that will save money, save time and save
lives."
Pharmacogenetics helps physicians determine how an individual patient
will respond to an individual drug, and at what dose. AssureRx analyzes not
just one gene, but several genes to predict how patients will respond to
medicines. The patent-pending technology takes many genetic variables into
consideration and translates the data into a report for doctors within 48
hours of receiving a sample from a patient.
"Until now, doctors have had to determine the safety and effectiveness
of psychotropic drug selection and dosing for an individual patient through
trial and error," said David Mrazek, M.D., Chair, Mayo Clinic Department of
Psychiatry and Psychology. "This technology allows for a personalized
patient report based on known science and the specific genetic makeup of
the individual patient. The report outlines metabolic factors and drug
response information."
Investors include Queen City Angels (lead), CincyTech USA, the Health
Foundation of Greater Cincinnati, Blue Chip Venture Company, Cincinnati
Children's Tomorrow Fund and individual investors.
"We liked what we saw in terms of the science, the research partners,
the business plan, the executive team and the market potential," said John
McIlwraith of Blue Chip Venture Company. "Personalized medicine is clearly
an emerging trend in patient care. We're happy to be in at the forefront of
this exciting opportunity with AssureRx, and we're confident that the
company will become a leader in the field."
About AssureRx
Cincinnati-based AssureRx, LLC, is a personalized medicine company
dedicated to helping physicians determine the right drug at the right dose
for individual patients suffering from a range of medical conditions. The
company was founded in June 2006 to license and commercialize
industry-leading personalized medicine technology of Cincinnati Children's
Hospital Medical Center and Mayo Clinic. The proprietary technology is
based on pharmacogenetics - the study of the genetic factors that influence
an individual's response to drug treatments - as well as evidence-based
medicine and clinical pharmacology. The result is a trusted guide that
helps doctors select the right drug at the right dose right now. AssureRx
can be found on the Web at http://www.assurerx.biz.
SOURCE AssureRx
 back to top
Related links:
http://www.assurerx.biz
CONTACT:
Laura Phillips, +1-513-721-5353,
lphillips@powersagency.com, for AssureRx
|
